Last updated: September 5, 2026
Latanoprostene bunod, marketed in the United States as Vyzulta by Bausch + Lomb, is a premium glaucoma treatment with a differentiated nitric-oxide mechanism. Its commercial trajectory has been positive but remains constrained by generic prostaglandin competition, formulary access, and the absence of broad first-line prescribing. U.S. product sales have grown from launch-stage levels to more than $100 million annually, while patent and regulatory protections provide a runway for continued branded sales before generic substitution becomes material.
What is the FDA status of latanoprostene bunod?
Latanoprostene bunod ophthalmic solution 0.024% is FDA-approved for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product is administered once daily in the affected eye or eyes.[1]
| Metric |
Detail |
| Active ingredient |
Latanoprostene bunod |
| Brand |
Vyzulta |
| Dosage form |
Ophthalmic solution, 0.024% |
| Therapeutic area |
Glaucoma and ocular hypertension |
| FDA approval |
November 2, 2017 |
| Original developer |
Nicox S.A. |
| U.S. commercial partner |
Bausch + Lomb |
| Administration |
One drop once daily |
| Mechanism |
Prostaglandin analog and nitric-oxide-mediated trabecular outflow improvement |
Latanoprostene bunod is converted to latanoprost acid and a nitric oxide-donating moiety. The dual mechanism is intended to increase uveoscleral outflow through the prostaglandin pathway while also improving trabecular outflow through nitric oxide signaling.[1]
The product entered a market dominated by generic latanoprost, generic bimatoprost, and generic travoprost. Its commercial rationale depends on incremental efficacy, once-daily dosing, tolerability, physician familiarity, and continued access for patients who do not achieve adequate pressure control with older therapies.
How has Vyzulta revenue developed?
Vyzulta revenue has followed a gradual adoption curve rather than a rapid launch. Bausch + Lomb has reported increasing sales as the product gained formulary coverage and ophthalmologist adoption.
| Fiscal year |
Approximate Vyzulta revenue |
Commercial interpretation |
| 2019 |
About $50 million |
Early market penetration |
| 2020 |
About $70 million |
Continued specialist adoption |
| 2021 |
About $85 million |
Expansion despite pandemic-related office disruption |
| 2022 |
About $110 million |
Increased prescription volume and access |
| 2023 |
About $125 million |
Sustained growth in the U.S. glaucoma franchise |
| 2024 |
Approximately $140 million or more |
Continued branded growth, subject to final company reporting classifications |
Bausch + Lomb reports Vyzulta within its prescription medicines portfolio. The company’s filings indicate that growth has been driven primarily by higher prescription demand and expanded commercial execution rather than major price increases.[2][3]
The product remains a mid-sized asset within Bausch + Lomb’s portfolio. Its value is strategic because ophthalmology is the company’s core commercial area, and Vyzulta can be sold through the same specialist, payer, and distribution infrastructure used for other eye-care products.
What market forces affect latanoprostene bunod?
Generic prostaglandin competition
The largest market constraint is the availability of low-cost generic prostaglandin analogs. Latanoprost is widely used as an initial treatment for open-angle glaucoma and ocular hypertension. Generic products have established physician familiarity and low payer cost.
Vyzulta must therefore justify its higher branded cost through one or more of the following factors:
- Greater intraocular-pressure reduction in selected patients.
- Additional trabecular outflow activity from nitric oxide donation.
- Use in patients inadequately controlled on a conventional prostaglandin.
- Once-daily administration.
- Commercial copay support and payer contracting.
- Avoidance of treatment escalation to multiple agents or surgery.
The product is better positioned as a differentiated branded option than as a direct replacement for generic latanoprost across the full treated population.
Disease prevalence
Glaucoma is a chronic, age-associated disease requiring long-term treatment. The eligible patient population is large, but prescription value is moderated by the availability of inexpensive generics. The addressable market for Vyzulta is therefore the subset of patients who need additional pressure reduction, have inadequate response or tolerability to existing therapies, or are managed by physicians willing to use a premium branded prostaglandin.
Physician adoption
Ophthalmologists control most prescribing decisions. Primary-care adoption has limited commercial relevance because glaucoma treatment is generally managed by eye-care specialists. This creates a concentrated promotional market, which lowers the scale required for commercial coverage but increases dependence on specialist sales execution.
Payer access
Commercial insurance coverage and Medicare Part D placement materially affect net sales. Vyzulta’s list price is less relevant than its net price after rebates, copay programs, and coverage restrictions. Prior authorization or non-preferred formulary status can delay use after a physician writes a prescription.
When does latanoprostene bunod lose exclusivity?
Vyzulta’s U.S. regulatory exclusivity has already expired, but patent protection may continue to limit generic entry.
The five-year new chemical entity exclusivity period associated with the 2017 FDA approval ended in 2022. Any pediatric exclusivity would add six months only if granted for qualifying pediatric studies. Regulatory exclusivity is separate from patent protection and does not itself establish the date of generic launch.
The commercially important question is whether an ANDA applicant can obtain approval with a Paragraph IV certification or must wait for relevant patents to expire.
What patents protect Vyzulta?
Vyzulta has been protected by patents directed to the active compound, ophthalmic compositions, and methods of treating elevated intraocular pressure. The relevant estate originated with Nicox and was licensed for commercialization to Bausch + Lomb.[4]
Publicly available FDA Orange Book records and patent databases should be reviewed together because:
- The Orange Book identifies patents submitted by the NDA holder.
- The listed expiration date may differ from the earliest compound patent expiration.
- A later formulation or method patent can remain relevant after an earlier compound patent expires.
- Patent listing does not guarantee enforceability or prevent an approved ANDA.
- Patent-term adjustment and pediatric exclusivity can change the effective timing.
The estate is commercially meaningful but narrower than the patent position of a newly launched small molecule. Latanoprostene bunod is a single-molecule ophthalmic product with limited formulation complexity. A generic applicant could seek approval through an ANDA if it can address the listed patents and demonstrate pharmaceutical equivalence.
Are there Paragraph IV challenges to Vyzulta?
No major publicly disclosed Vyzulta Paragraph IV litigation is identified in the cited Bausch + Lomb annual-report disclosures through the 2024 reporting period.[2][3] The absence of disclosed litigation does not establish that no certification has been filed. It indicates that no material Paragraph IV dispute has been reported as a significant corporate litigation event.
A Paragraph IV challenge would create several potential outcomes:
| Scenario |
Commercial effect |
| No challenge before patent expiry |
Branded revenue continues until ordinary generic entry |
| Paragraph IV with settlement |
Generic entry could occur before listed patent expiry under agreed terms |
| Paragraph IV litigation won by Bausch + Lomb |
Entry is delayed until patent expiry or invalidation |
| Paragraph IV litigation won by challenger |
Earlier generic launch and rapid price erosion |
| Non-infringement or Section viii carve-out |
Generic may enter for non-protected uses, depending on labeling |
How strong is the Vyzulta patent estate?
The patent estate is moderately strong commercially, with greater value in delaying substitution than in creating a permanent barrier to competition.
Its strengths are:
- A differentiated active ingredient.
- Combination of prostaglandin and nitric-oxide pharmacology.
- Specialist prescribing and chronic use.
- Brand recognition within ophthalmology.
- Potential difficulty reproducing the exact active ingredient and product specifications.
Its weaknesses are:
- Small-molecule status, which allows an ANDA route rather than a biosimilar pathway.
- Generic alternatives in the same therapeutic class.
- Limited ability to prevent substitution once core patents expire.
- Potential for a generic applicant to challenge formulation or method-of-use claims.
- Payer pressure on premium glaucoma products.
Manufacturing complexity can delay entry if the active ingredient or finished ophthalmic product has difficult quality attributes. It is unlikely to create the durable barrier associated with biologics, complex injectables, or device-integrated delivery systems.
What is the biosimilar and generic risk?
Biosimilar risk is not relevant because latanoprostene bunod is a chemically synthesized small molecule, not a biologic. The relevant threat is ANDA-based generic competition.
Generic risk is currently lower than it would be after an approved ANDA reaches the market because Vyzulta has differentiated chemistry and no widely reported generic launch. That risk increases sharply once a first generic is approved.
Ophthalmic products can experience rapid price erosion after generic entry. The erosion may be moderated by:
- Limited manufacturing capacity.
- Brand loyalty among ophthalmologists.
- Formulary restrictions against switching.
- Prescriber concern about device or bottle performance.
- Patient persistence with an established therapy.
The most likely generic-launch pattern is an initial period of limited competition followed by additional ANDA approvals if the first entrant demonstrates commercial demand.
Which companies compete with latanoprostene bunod?
Vyzulta competes with multiple categories rather than one directly comparable branded product.
| Competitor category |
Examples |
Competitive threat |
| Generic prostaglandins |
Latanoprost, bimatoprost, travoprost |
Low-cost first-line treatment |
| Branded prostaglandins |
Travatan Z, Lumigan where branded access remains |
Differentiated branded alternatives |
| Fixed combinations |
Rocklatan, Simbrinza, Cosopt and generics |
Pressure reduction with fewer bottles |
| Rho-kinase inhibitors |
Netarsudil products |
Alternative mechanism |
| Laser therapy |
Selective laser trabeculoplasty |
Drug-sparing treatment option |
| Surgery and implants |
MIGS procedures and sustained-delivery systems |
Long-term reduction in topical-drug use |
Rocklatan, which combines netarsudil and latanoprost, is the closest branded pharmacologic comparator in terms of combining prostaglandin activity with an additional outflow-related mechanism. Its competitive advantage is combination therapy in a single bottle; its disadvantages include tolerability issues associated with netarsudil and a higher branded cost.
What licensing deal supports Vyzulta?
Nicox licensed North American commercialization rights for latanoprostene bunod to Bausch + Lomb. The arrangement included development, regulatory, and commercial milestones, as well as royalty economics for Nicox.[4]
The deal gave Bausch + Lomb access to a differentiated glaucoma asset without originating the underlying discovery program. It gave Nicox a commercial route through an established ophthalmology company. The economic structure also reduced the need for Nicox to fund a large U.S. commercial organization.
For Bausch + Lomb, the license expanded its prescription ophthalmology portfolio. For Nicox, Vyzulta has been a material source of royalty and milestone value relative to the company’s smaller operating base.
What is the likely financial trajectory for Vyzulta?
Vyzulta should remain a growth asset while branded prescriptions expand and before meaningful generic substitution. Growth is likely to moderate from percentage rates seen during the initial commercial ramp because the product now operates from a larger revenue base.
Base-case trajectory
The base case includes:
- Continued prescription growth in the U.S.
- Stable or improving formulary coverage.
- Gradual expansion among patients inadequately controlled on generic prostaglandins.
- No near-term generic launch.
- Increasing payer pressure as gross-to-net discounts rise.
Under this scenario, annual revenue can continue to increase modestly before reaching a plateau in the later part of the decade.
Downside case
The downside case includes an earlier Paragraph IV challenge, successful patent invalidation, or a generic launch before the market has fully matured. A first generic could reduce U.S. branded revenue materially within several quarters. The decline would likely be faster than the pre-generic growth curve because glaucoma patients can be switched at refill.
Upside case
The upside case depends on stronger physician adoption in patients with inadequate response to standard prostaglandins, expanded international commercialization, and sustained payer access. A label expansion or evidence showing clinically meaningful benefit in a defined patient subgroup could improve the product’s treatment position, but no such expansion should be assumed without an FDA action.
How does Vyzulta compare with other Bausch + Lomb products?
Vyzulta is smaller than Bausch + Lomb’s largest consumer and prescription brands but has strategic value because of its specialty focus and recurring chronic-use profile.
| Product characteristic |
Vyzulta |
| Revenue model |
Chronic prescription ophthalmology |
| Patient persistence |
Potentially high because glaucoma requires long-term treatment |
| Price positioning |
Premium versus generic prostaglandins |
| Commercial concentration |
Ophthalmologists and optometrists |
| Main risk |
Generic substitution and payer restrictions |
| Manufacturing risk |
Moderate relative to ordinary ophthalmic solutions |
| Regulatory pathway for competitors |
ANDA, not biosimilar |
| Strategic fit |
Strong alignment with Bausch + Lomb ophthalmology |
Vyzulta’s revenue is more durable than a short-course ophthalmic product because treatment is chronic. Its margin profile is vulnerable to rebates and future generic entry, but the product does not face the same near-term patent cliff as an asset whose core exclusivity has already expired and whose generic alternatives are already available.
What is the geographic coverage of latanoprostene bunod?
The United States remains the principal commercial market. International availability depends on country-specific approvals, reimbursement, licensing, and distribution arrangements. Bausch + Lomb and Nicox have used different commercialization structures across territories, so global revenue should not be inferred from U.S. performance.
The United States offers the highest near-term value because of the size of the treated glaucoma population and the established Bausch + Lomb commercial infrastructure. International expansion can add revenue but may produce lower net pricing and slower reimbursement-driven uptake.
Key Takeaways
- Latanoprostene bunod is marketed in the United States as Vyzulta by Bausch + Lomb.
- FDA approval was granted in November 2017 for open-angle glaucoma and ocular hypertension.
- U.S. revenue increased from roughly $50 million in 2019 to more than $100 million annually by 2022, with further growth reported through 2024.
- The product’s commercial differentiation is its nitric-oxide-donating prostaglandin mechanism.
- Generic latanoprost and other prostaglandin analogs remain the primary market constraint.
- Regulatory exclusivity has expired, making patent duration and Paragraph IV activity the key legal variables.
- Vyzulta faces ANDA-based generic risk, not biosimilar risk.
- No major publicly disclosed Paragraph IV litigation was identified in the cited company disclosures through the 2024 reporting period.
- The financial outlook is positive before generic entry but exposed to rapid revenue erosion after a competing ANDA reaches the market.
- The Nicox-Bausch + Lomb licensing arrangement gives Bausch + Lomb commercial control in key markets and provides Nicox with royalty-related economics.
FAQs About Latanoprostene Bunod Market and Financial Outlook
Is latanoprostene bunod the same as latanoprost?
No. Latanoprostene bunod is a distinct active ingredient that releases latanoprost acid and a nitric-oxide-donating component. Latanoprost releases latanoprost acid but does not have the same nitric-oxide mechanism.
Who owns Vyzulta?
Bausch + Lomb commercializes Vyzulta in the United States under rights licensed from Nicox. Ownership and commercialization rights vary by territory and contractual arrangement.
Can generic manufacturers make latanoprostene bunod?
Yes. Because latanoprostene bunod is a small molecule, a qualified manufacturer can seek FDA approval through an ANDA, subject to pharmaceutical-equivalence, patent, labeling, and manufacturing requirements.
Is Vyzulta covered by Medicare?
Coverage depends on the patient’s Medicare Part D plan, formulary tier, utilization controls, and prior-authorization requirements. Coverage is not uniform across plans.
What is the main investment risk for Vyzulta?
The main risk is earlier-than-expected generic entry. A Paragraph IV challenge, patent settlement, patent invalidation, or successful non-infringement position could accelerate substitution and reduce branded revenue.
References
- U.S. Food and Drug Administration. (2017). Vyzulta (latanoprostene bunod ophthalmic solution) prescribing information. https://www.accessdata.fda.gov
- Bausch + Lomb Corporation. (2024). 2023 annual report. https://ir.bausch.com
- Bausch + Lomb Corporation. (2025). 2024 annual report. https://ir.bausch.com
- Nicox S.A. (2024). Universal registration document and annual financial report. https://www.nicox.com
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
